Get the Stockscreener App
16.01
10.26%
1.49
After Hours:
15.37
-0.64
-4.00%
Tourmaline Bio Inc stock is traded at $16.01, with a volume of 348.30K.
It is up +10.26% in the last 24 hours and down -12.32% over the past month.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
See More
Previous Close:
$14.52
Open:
$14.53
24h Volume:
348.30K
Relative Volume:
1.07
Market Cap:
$361.91M
Revenue:
-
Net Income/Loss:
$11.77M
P/E Ratio:
27.68
EPS:
0.5785
Net Cash Flow:
$-19.23M
1W Performance:
+32.31%
1M Performance:
-12.32%
6M Performance:
-45.04%
1Y Performance:
-4.02%
1-Day Range:
$14.53
$16.11
1-Week Range:
$11.66
$16.11
52-Week Range:
$11.56
$29.79
Tourmaline Bio Inc Stock (TRML) Company Profile
Name
Tourmaline Bio Inc
Sector
Industry
Phone
646-481-9832
Address
27 WEST 24TH STREET, NEW YORK
Compare TRML with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRML
Tourmaline Bio Inc
|
16.01 | 361.91M | 0 | 11.77M | -19.23M | 0.5785 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Nov-11-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-15-23 | Initiated | Jefferies | Buy |
| Dec-04-23 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Oct-31-23 | Initiated | Guggenheim | Buy |
| Oct-25-23 | Initiated | Piper Sandler | Overweight |
| Oct-20-22 | Initiated | H.C. Wainwright | Buy |
| Jul-05-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
View All
Tourmaline Bio Inc Stock (TRML) Latest News
Here's Why We're Not Too Worried About Tourmaline Bio's (NASDAQ:TRML) Cash Burn Situation - Yahoo Finance
Vanguard Group Inc. Boosts Stock Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Wellington Management Group LLP Buys 8,001 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Stock Position Increased by Wellington Management Group LLP - Defense World
Wellington Management Group LLP Acquires 813 Shares of Ferrovial SE (NASDAQ:FER) - Defense World
Corebridge Financial Inc. Trims Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Wellington Management Group LLP Raises Position in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Corebridge Financial Inc. Has $199,000 Holdings in Red Violet, Inc. (NASDAQ:RDVT) - Defense World
KLP Kapitalforvaltning AS Invests $47,000 in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Corebridge Financial Inc. Lowers Position in Chatham Lodging Trust (NYSE:CLDT) - Defense World
Franklin Resources Inc. Sells 5,012 Shares of Genworth Financial, Inc. (NYSE:GNW) - Defense World
7,700 Shares in Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) Acquired by KLP Kapitalforvaltning AS - Defense World
Corebridge Financial Inc. Has $213,000 Position in Celcuity Inc. (NASDAQ:CELC) - Defense World
Corebridge Financial Inc. Sells 557 Shares of Net Lease Office Properties (NYSE:NLOP) - Defense World
Franklin Resources Inc. Boosts Stock Holdings in Aviat Networks, Inc. (NASDAQ:AVNW) - Defense World
Arhaus, Inc. (NASDAQ:ARHS) Shares Bought by Vanguard Group Inc. - Defense World
American Century Companies Inc. Purchases New Stake in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Can TRANQUILITY Data Propel Tourmaline Bio's Stock Price? - RTTNews
Truist Cuts Price Target on Tourmaline Bio to $63 From $74, Keeps Buy Rating - marketscreener.com
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Rating of “Buy” by Brokerages - Defense World
Talaris Therapeutics stock hits 52-week low at $11.85 By Investing.com - Investing.com Canada
Prudential Financial Inc. Cuts Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Tourmaline Bio: We Should Wait For Upcoming Phase 2b Trial Data - Seeking Alpha
Should You Invest in H&R Block Inc (HRB) Now? - News Heater
Swiss National Bank Takes Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Leading Factor Driving the Thyroid Eye Disease (TED) Market in 2025: Thyroid Disorders And Their Influence ... - WhaTech
ProfittoPath - TradingView
Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Sold by AlphaQuest LLC - Defense World
Tourmaline Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Alumis Inc. (NASDAQ:ALMS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Tourmaline Bio (NASDAQ:TRML) Stock Price Expected to Rise, Wedbush Analyst Says - Defense World
HC Wainwright Raises Tourmaline Bio (NASDAQ:TRML) Price Target to $50.00 - Defense World
H.C. Wainwright raises Tourmaline Bio stock target to $50 By Investing.com - Investing.com Canada
Tourmaline Bio price target raised to $43 from $42 at Wedbush - TipRanks
H.C. Wainwright raises Tourmaline Bio stock target to $50 - Investing.com India
Wedbush Lifts Price Target on Tourmaline Bio to $43 From $42, Keeps Outperform Rating - Marketscreener.com
Novo Nordisk (0QIU) Gets a Buy from UBS - The Globe and Mail
Tourmaline Bio’s 2024 Financial Results and Strategic Advances - TipRanks
Tourmaline Bio shares fall as Q4 loss widens - Investing.com
Tourmaline Bio shares fall as Q4 loss widens By Investing.com - Investing.com UK
TOURMALINE BIO Earnings Results: $TRML Reports Quarterly Earnings - Nasdaq
Tourmaline Bio, Inc. SEC 10-K Report - TradingView
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times
Tourmaline Bio's cash position to provide cash runway into second half of 2027 -March 13, 2025 at 07:39 am EDT - Marketscreener.com
Tourmaline Bio, Inc. Announces Over-Enrolled Phase 2 TRANQUILITY Trial and Strengthens Cardiovascular Scientific Advisory Board Amid Positive Financial Outlook - Nasdaq
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business - Bluefield Daily Telegraph
Tourmaline Bio Secures 2.5-Year Cash Runway with $294M, Accelerates Key Clinical Trials - StockTitan
Tourmaline Bio (TRML) Projected to Post Earnings on Tuesday - Defense World
Wedbush Forecasts Tourmaline Bio FY2024 Earnings - Defense World
Tourmaline Bio (NASDAQ:TRML) Research Coverage Started at Wedbush - Defense World
Tourmaline Bio Inc Stock (TRML) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):